Hopefully they follow thru with some major publications this year like Stamler mentioned previously. Who knows though. I would really like to get an update on the clinical path for pbt2. can it move forward right away in acute settings? are they meeting with fda in regards to chronic administration?
Stamler and Bradbury work still for TEVA, page-2
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $3.631K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 60 | 81072032 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 2447647 | 3 |
View Market Depth
| Last trade - 15.59pm 18/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |